Pearl River Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Pearl River Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,604	Closed	-$40K	–	507
2019 Q1	$40K	Buy	+1,604	New	+$40.2K	0.1%	260

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Pearl River Capital's CLVS Position: Q2 2019 in Review

Pearl River Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 1,604 shares — an estimated $40K sold.

Pearl River Capital first reported a position in CLVS in Q1 2019 and held it in 1 quarter. The position peaked at $40K in Q1 2019. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

Pearl River Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
Pearl River Capital sold 1,604 Clovis Oncology, Inc. shares in Q2 2019, an estimated $40K.
Pearl River Capital first reported a position in Clovis Oncology, Inc. in Q1 2019 and held it in 1 quarter.
Pearl River Capital's Clovis Oncology, Inc. position peaked at $40K in Q1 2019.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.